UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026768
Receipt number R000030722
Scientific Title A randomized controlled trial to evaluate the effectiveness of personalized genetic breast cancer risk feedback for non-breast cancer women
Date of disclosure of the study information 2017/04/17
Last modified on 2023/04/03 11:34:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized controlled trial to evaluate the effectiveness of personalized genetic breast cancer risk feedback for non-breast cancer women

Acronym

Breast cancer risk feedback RCT

Scientific Title

A randomized controlled trial to evaluate the effectiveness of personalized genetic breast cancer risk feedback for non-breast cancer women

Scientific Title:Acronym

Breast cancer risk feedback RCT

Region

Japan


Condition

Condition

Breast cancer prevention behavior

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the effectiveness of personalized genetic breast cancer risk feedback for non-breast cancer women

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Frequency of breast self-examination

Key secondary outcomes

Frequency and type of breast cancer screening, Lifestyle changes (BMI, physical activity, alcohol consumption, etc)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Gene Other

Interventions/Control_1

Personalized breast cancer risk feedback based on individuals' genetic polymorohism and their lifestyles

Interventions/Control_2

Personalized breast cancer risk feedback based on individuals' lifestyles

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

70 years-old >

Gender

Female

Key inclusion criteria

1.Individuals who had a diagnostic test at Aichi Cancer Center
2.Individuals who are not diagnosed with breast cancer
3.30-69 years old women
4.no past history of cancer
5. Individuals who sign the consent document after explanation of this study

Key exclusion criteria

1.Individuals who need regular follow-up after their initial medical examinations.
2.Individuals who had a commercial genetic testing

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Keitaro
Middle name
Last name Matsuo

Organization

Aichi Cancer Center Research Institute

Division name

Division of Molecular and Clinical Epidemiology

Zip code

464-8681

Address

1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan

TEL

052-764-9828

Email

molemed3@aichi-cc.jp


Public contact

Name of contact person

1st name Keitaro
Middle name
Last name Matsuo

Organization

Aichi Cancer Center

Division name

Division of Molecular and Clinical Epidemiology

Zip code

464-8681

Address

Nagoya

TEL

0528517750

Homepage URL

http://www.pref.aichi.jp/cancer-center/ri/01bumon/04idenshi_iryo/09c/homepage/index.html

Email

molemed3@aichi-cc.jp


Sponsor or person

Institute

Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization

Aichi Cancer Center

Address

Nagoya

Tel

0528517750

Email

irb@aichi-cc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

愛知県がんセンター研究所
Aichi Cancer Center Research Institute


Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

200

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2017 Year 03 Month 10 Day

Date of IRB

2016 Year 03 Month 16 Day

Anticipated trial start date

2017 Year 04 Month 17 Day

Last follow-up date

2035 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 03 Month 29 Day

Last modified on

2023 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030722


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name